Monitoring adverse events of the vaccination campaign against influenza A (H1N1) in the Netherlands

Drug Safety

Volumn 33, Issue 12, 2010, Pages 1097-1108

  Van Puijenbroek, Eugne P ^a   Broos, Nancy ^a   Van Grootheest, Kees ^a  

^a NETHERLANDS PHARMACOVIGILANCE CENTRE LAREB   (Netherlands)

Author keywords

Adverse reaction monitoring; Immunisation programmes; Influenza A virus vaccine H1N1, adverse reactions; Vaccines

Indexed keywords

INFLUENZA VACCINE;

ANAPHYLACTIC SHOCK; ARTICLE; BELL PALSY; CONGESTIVE CARDIOMYOPATHY; CONSUMER ATTITUDE; CONVULSION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENCEPHALITIS; GUILLAIN BARRE SYNDROME; HUMAN; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFORMATION PROCESSING; MULTIPLE SCLEROSIS; NETHERLANDS; NEURITIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; VASCULITIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BIAS (EPIDEMIOLOGY); CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG LABELING; DRUG MONITORING; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERNET; MASS VACCINATION; NATIONAL HEALTH PROGRAMS; NETHERLANDS; PANDEMICS; PHARMACOEPIDEMIOLOGY; QUALITY CONTROL; TIME FACTORS;

EID: 78549232274     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11539270-000000000-00000     Document Type: Article

References (24)

1. World Health Organization. Statement from WHO Global Advisory Committee on Vaccine Safety about the safety profile of pandemic influenza A (H1N1) 2009 vaccines [online]. Available from URL http://www.who.int/csr/resources/ publications/swineflu/gacvs-statement-20091218/ en/ [Accessed 2010 Aug 19].
2. EPAR Focetria. European Medicines Evaluation Agency [online]. Available from URL: http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product- Informa tion/human/000710/WC500023749.pdf [Accessed 2009 Dec 18]
3. Vaccinatiecampagne Nieuwe Influenza A (H1N1) afgerond [online]. Available from URL: http://www.grieppandemie. nl/home/nieuws/cid(803)/ [Accessed 2010 Jun 2]
4. Dutch Health Council. Vaccination against pandemic Influenza A (H1N1) 2009: target groups and prioritization (1). 17 August 2009 [online]. Available from URL: http:// www.gezondheidsraad.nl/sites/default/files/200910-0.pdf [Accessed 2010 Feb 22]
5. EPAR Pandemrix. European Medicines Evaluation Agency [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Informa tion/human/000832/WC500038121.pdf [Accessed 2009 Dec 18]
6. Vaccinaties en screening: Opkomst 1e vaccinatieronde Nieuwe Influenza A (H1N1) door GGD'en 2009, kinderen (6 mnd-4 jr)-Nationale Atlas Volksgezondheid. RIVM Nationale Atlas Volksgezondheid [online]. Available from URL http://www.zorgatlas.nl/preventie/vaccinaties-en-screen ing/opkomst-1e- vaccinatieronde-nieuwe-influenza-a-h1n1-door-ggd-en-2009-huisgenoten/ [Accessed 2010 Sep 20].
7. Nationale Atlas Volksgezondheid. Vaccinaties en screening: opkomst 2e vaccinatieronde Nieuwe Influenza A (H1N1) door GGD'en 2009, kinderen (6 mnd-4 jr). RIVM Natio-nale Atlas Volksgezondheid [online]. Available from URL: http://www.zorgatlas.nl/preventie/vaccinaties-en-screening/ opkomst-2de- vaccinatieronde-nieuwe-influenza-a-h1n1-door-ggd-en-2009-huisgenoten/ [Accessed 2010 Sep 10]
8. Offit PA, Davis RL, Gust D. Vaccine safety. In: Plotkin S, Orenstein W,Offit PA, editors. Vaccines. Philadelphia (PA): Saunders Elsevier, 2008: 1629-50
9. van Grootheest AC, de Graaf L, de Jong-van den Berg LT. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf 2003; 26 (4): 211-7
10. de Langen J, van Hunsel F, Passier A, et al. Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf 2008; 31 (6): 515-24
11. van Grootheest CA, Broos N. Vaccinatiecampagne tegen Nieuwe Influenza A (H1N1): veiligheidsbewaking door de huisarts noodzakelijk. Medisch Contact 2009; 64 (43): 1257-60
12. The use of the WHO-UMC system for standardised case causality assessment. World Health Organization (WHO), Uppsala Monitoring Centre, 2010 [online]. Available from URL: www.who-umc.org/graphics/4409.pdf [Accessed 2010 Mar 10]
13. Van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11 (1): 3-10
14. Stricker BH Ch, Tijssen JGP. Serum sickness-like reactions to cefaclor. J Clin Epidemiol 1992; 45 (10): 1177-84
15. Moore N, Kreft-Jais C, Haramburu F, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 1997; 44 (5): 513-8
16. CHMP recommendations for the pharmacovigilance plan as part of the risk management plan to be submitted with the marketing authorisation application for a pandemic influenza vaccine. Revision 1.1 (version date 24-9-2009).
17. European Medicines Agency 2009 [online]. Available from URL, http://www. emea.europa.eu/docs/en-GB/document-library/Report/2010/01/WC500051739.pdf. Accessed 2010 Sep 9.
18. Eurosurveillance editorial team. ECDC in collaboration with the VAESCO consortium to develop a complementary tool for vaccine safety monitoring in Europe. Euro-surveillance 2010 [online]. Available from URL http://www. eurosurveillance.org/images/dynamic/EE/V14N39/art19345. pdf [Accessed 2010 Sep 9].
19. van Grootheest AC, de Jong-van den Berg LTW. Patients' role in reporting adverse drug reactions. Expert Opin Drug Saf 2004; 3 (4): 363-8
20. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Rainsford KD, Velo GP, editors. Advances in inflammatory research. New York: Raven Press, 1984: 1-7
21. Pariente A, Gregoire F, Fourrier-Reglat A, et al. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 2007; 30 (10): 891-8
22. van der Heijden PG, van Puijenbroek EP, van Buuren S, et al. On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of underreporting on odds ratios. Stat Med 2002; 21 (14): 2027-44
23. Broos N, van Puijenbroek EP, van Grootheest K. Fever following immunization with influenza A (H1N1) vaccine in children: a survey-based study in the Netherlands. Drug Saf 2010; 33 (12): 1109-15
24. Johansson K, Olsson S, Hellman B, et al. An analysis of Vigimed, a global e-mail system for the exchange of phar-macovigilance information. Drug Saf 2007; 30 (10): 883-9